ESSL leading study to find where and why damaging hail is getting worse
Wiener Neustadt, Austria jan 12, 2026 - First comprehensive global study of very large hail in a changing climate reveals contrasting trends and different causes.

For the first time, scientists have modelled the occurrence of hail larger than 5 cm globally. European storm researchers analysed long-term trends of hail frequency and associated economic losses over the past 30 years. While very large hail is most common in parts of South America, the United States and South Africa, the study reveals that the strongest increase in frequency has occurred in Europe. In contrast, some regions of the Southern Hemisphere have experienced a decline. Changes in atmospheric moisture near the surface are primarily responsible for these trends.
Although hail-related losses have increased across Europe, with several multi-billion-dollar losses over recent years, the meteorological changes are only partly responsible for this increase. Rising losses are also driven by greater exposure and vulnerability: as more homes and infrastructure are built in hazard-prone areas, the potential for damage increases. This effect is a key driver of rising losses in the United States and along Australia’s coastlines.
The study was published in Nature Geoscience and lead-authored by the European Severe Storms Laboratory (ESSL) in collaboration with experts from the Adam Mickiewicz University of Poznań (Poland) and German reinsurer Munich Re (Germany).
The map illustrates the mean trend in the annual number of very large hail events per decade between 1950 and 2023. Hail stripes showing the yearly occurrence of very large hail are provided for six metropolitan regions.
Reference: Battaglioli, F., Taszarek, M., Groenemeijer, P. et al. Contrasting trends in very large hail events and related economic losses across the globe. Nat. Geosci. 19, 52–58 (2026). https://doi.org/10.1038/s41561-025-01868-0
www.essl.org/cms/about-us/press
Link to study: https://doi.org/10.1038/s41561-025-01868-0e
Contacts
Stefan EisenbachPress ContactESSL
Tel:+436 647 310 33 44stefan.eisenbach@essl.orgwww.essl.org/cms/Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press Release
Zoetermeer, Netherlands - 13 January 2026 - Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 13:27:37 CET | Press Release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:20:00 CET | Press Release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing. The anniversary edition underlines how natural remedies, therapeutic landscapes and evidence-based spa medicine represent a distinctive European strength with growing relevance for public health systems. Across Europe, medical spas are increasingly recognised as complementary health infrastructures supporting prevention, rehabilitation and long-term quality of life. “Medical spas today are strategic health infrastructures supporting prevention, rehabilitation and long-term wellbeing,” says Dr Siyka Katsarova, President of ESPA and Advisor to the EU’s New Lifestyle Strategy. The publication showcases Europe’s exceptional therapeutic diversity — ranging from thermal and mineral waters, climate therapy and thalassotherapy t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
